The method is able to produce nano graphene platelets with a thickness thinner than 100nm and in many cases thinner than 10 nm or as thin as 0.34 nm to 1.02 nm. This method allows the NGP material to be used in applications ranging from bucky paper, mat, thin film and lamina to nanocomposites.
The PiezoFlare 1200 is a revolutionary manufacturing technology to produce chips with precise actuation functionality for various new applications like, inkjet printheads, pico projectors, RF MEMS and various sensing applications.
The Malaysian Industry-Government Group for High Technology (MIGHT) is collaborating with NanoMalaysia Bhd to identify potential offset programme recipients for nanotechnology-based industries from various sectors.
The name of the new business unit, Lumineq, stands for Beneq's strong commitment to thin film electroluminescence (TFEL) technology and the industrial production of other ALD (atomic layer deposition) enabled products. These products will be offered in addition to Beneq's existing product portfolio.
CYTOO S.A., a life science systems and tools company that offers disruptive solutions for cell-based assays and High Content Screening (HCS), will launch the CYTOOplates Motility, based on CYTOO's 2D+ Cell Culture Platform with its adhesive micropatterns, at the ASCB 2012 Annual meeting in San Francisco, USA.
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostic products, today announced the completion of a $15.3 million Series E Preferred Stock issuance.
Elemental Mapping is the first expansion of the Phenom proX EDS-technology. The new 2.0 Element Identification (EID) software and the introduction of Elemental Mapping create a state of the art combination of hardware integration and dedicated software.
Genisphere and the nonprofit Lankenau Institute for Medical Research (LIMR), which are already making progress together on identifying Inflammatory Bowel Disease biomarkers, have partnered to develop nanotherapeutics targeting cancers and eye diseases.